Peter Ellmark - Department of Immunotechnology;Lund University;Department of Immunotechnology, Lund University

基本信息

浏览量：39

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 111 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Antigenic Peptide Delivery to Antigen-Presenting Cells Using a CD40-coiled Coil Affinity-Based Platform

Barnabas Nyesiga, Karin Hägerbrand, Laura Varas,Anette Gjörloff Wingren,Mats Ohlin,Peter Ellmark,Laura von Schantz

Drug deliveryno. 1 (2025): 2486340-2486340

引用0浏览0WOS引用

First-in-human, Multicenter, Open-Label, Phase I Study of ATOR-1017 (evunzekibart), a 4-1BB Antibody, in Patients with Advanced Solid Malignancies

Ana Carneiro,Amanda Hahn,Peter Ellmark,Karin Enell Smith,Lena Schultz,Sumeet Ambarkhane,Jeffrey Yachnin,Gustav J. Ullenhag

JOURNAL FOR IMMUNOTHERAPY OF CANCERno. 1 (2025)

引用0浏览0WOS引用

Abstract C038: Interim Pharmacodynamic Analyses of Mitazalimab in Combination with FOLFIRINOX in First-Line Metastatic Pancreatic Ductal Adenocarcinoma (mpdac) Identify CD4 Effector T Cells As a Correlate of Treatment Outcomes

Max M. Wattenberg,Karin Enell Smith,Yago Pico de Coana,David Gomez Jimenez,Malin Carlsson,Sumeet Vijay Ambarkhane,Peter Ellmark,Gregory L. Beatty

Cancer Researchno. 2_Supplement (2024)

引用0浏览0引用

ATOR-4066, a Neo-X-Prime™ Bispecific Antibody Targeting CD40 and CEACAM5, Induces Tumor Localized Immune Cell Activation in Preclinical in Vivo Tumor Model

Hampus Andersson, Ida Uddback,Mona Celander,Maria Johansson,Lill Ljung,Anneli Nilsson, Amulya Krishna Shetty,David Gomez Jimenez,Mattias Levin,Sara Fritzell,Laura von Schantz,Malin Lindstedt,Karin Hagerbrand,Anette Sundstedt,Peter Ellmark

Cancer Research（2024）

引用0浏览0引用

Interim Pharmacodynamic Analyses of Mitazalimab in Combination with FOLFIRINOX in First-Line Metastatic Pancreatic Ductal Adenocarcinoma (mpdac) Identify CD4 Effector T Cells As a Correlate of Treatment Outcomes

Max M. Wattenberg,Karin Enell Smith,Yago Pico de Coana,David Gomez Jimenez,Malin Carlsson,Sumeet Vijay Ambarkhane,Peter Ellmark,Gregory L. Beatty

CANCER RESEARCHno. 2 (2024)

引用0浏览0引用

Mitazalimab, a Potent CD40 Agonist in Combination with FOLFIRINOX Demonstrates Changes Consistent with Increased Immune Activation in TME and Peripheral Blood in a Preclinical Pancreatic Cancer Tumor Model

Karin Enell Smith,David Gomez Jimenez,Mia Thagesson,Anneli Nilsson,Yago Pico de Coana,Sumeet Ambarkhane,Peter Ellmark

Cancer Researchno. 6_Supplement (2024): 2376-2376

引用1浏览0引用

762 ATOR-4066, a Neo-X-Prime Bispecific Antibody Targeting CD40 and CEACAM5, Induces Myeloid and T-cell Dependent Anti-Tumor Activity and Synergizes with PD-1 Inhibition

Ida Uddbäck,Hampus Andersson,Lill Ljung,Anneli Nilsson, Amulya Krishna Shetty,David Gomez Jimenez,Malin Lindstedt,Karin Hägerbrand,Sara Frizell,Peter Ellmark

Regular and Young Investigator Award Abstracts (2024)

引用0浏览0引用

CD4 Effector T Cell Expansion to Identify Objective Responses to the CD40 Agonist Mitazalimab in Combination with Modified FOLFIRINOX (mffx) As First-Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma (mpdac) in the OPTIMIZE-1 Study

Max Miller Wattenberg,Karin Enell Smith,Yago Pico de Coana,David Gomez Jimenez,Sumeet Vijay Ambarkhane,Peter Ellmark,Gregory Lawrence Beatty

Journal of Clinical Oncology（2024）

引用0浏览0引用

Combining CD40 Agonist Mitazalimab with Mfolfirinox in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (OPTIMIZE-1): a Single-Arm, Multicentre Phase 1b/2 Study

Jean -Luc Van Laethem,Ivan Borbath,Hans Prenen,Karen Paula Geboes,Aurelien Lambert,Emmanuel Mitry,Philippe Alexandre Cassier,Jean-Frederic Blanc,Lorenzo Pilla,Jaime Feliu Batlle,Mercedes Rodriguez Garrote, Roberto Antonio Pazo-Cid,Inmaculada Gallego,Karin Enell Smith,Peter Ellmark,Yago Pico de Coana,Sumeet Vijay Ambarkhane,Teresa Macarulla

LANCET ONCOLOGYno. 7 (2024): 853-864

引用1浏览0WOS引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn